Background
Methods
Patient enrollment
Treatment and follow-up protocols
Pain and functional ability evaluation
Tumor progression evaluation
Statistical analysis
Results
Demographic data
Case no. | Age | Gender | Dose (mg)‡ | BMI (kg/m2) | Site of tumor | Treatment history |
---|---|---|---|---|---|---|
01† | 44 | Male | 80 | 30.04 | Lower back | Post-3rd surgery with S and SD |
02 | 51 | Female | 47 | 18.83 | Lower back | Post-1st surgery with S and PD |
03 | 30 | Female | 52 | 21.64 | Shoulder | Post-3rd surgery with S and PD |
04 | 23 | Male | 68 | 23.53 | Lower neck | Post-2nd surgery with S and PD |
05 | 55 | Female | 58 | 25.78 | Shoulder | Post-2nd surgery with S and PD |
06 | 45 | Female | 53 | 20.70 | Thigh | Post-3rd surgery with S and SD |
07 | 18 | Male | 60 | 20.05 | Shoulder | Post-1st surgery with S and PD |
08 | 56 | Female | 65 | 24.77 | Shoulder | Post-5th surgery with S and SD |
09 | 40 | Female | 58 | 22.65 | Forearm | Post-3rd surgery with S and PD |
10† | 20 | Male | 65 | 21.22 | Thigh | Post-3rd surgery with AS and PD |
Procedure-related and steroid-related complications
Serum triamcinolone levels, morning cortisol levels, and ACTH stimulation test results
Pain and functional ability scores and tumor progression
Case no. | Before injection† | After ILSI‡ | The 3rd-month after ILSI§ |
---|---|---|---|
02 | Progressive disease | Stable disease | Stable disease |
03 | Progressive disease | Stable disease | Progressive disease |
04 | Progressive disease | Stable disease | Stable disease |
05 | Progressive disease | Stable disease | Progressive disease |
06 | Stable disease | Stable disease | Stabile disease |
07 | Progressive disease | Progressive disease | Progressive disease |
08 | Stable disease | Stable disease | Stable disease |
09 | Progressive disease | Stable disease | Stable disease |